ATAngela To

Angela To

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela To has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function

    by Vincent Allain, Allison G. Rothrock, Pierre-Louis Bernard, William A. Nyberg, Alexis Talbot, Joseph J. Muldoon, Jing-Yi Chung, Angela To, Christopher R. Chang, Gabriella R. Kimmerly, et al.

    Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.

  • Open Access

    Modular pooled discovery of synthetic knockin sequences to program durable cell therapies

    by Franziska Blaeschke, Yan Yi Chen, Ryan Apathy, Bence Daniel, Andy Y. Chen, Peixin Amy Chen, Katalin Sandor, Wenxi Zhang, Zhongmei Li, Cody T. Mowery, et al.


  • Open Access

    Modular Pooled Discovery of Synthetic Knockin Sequences to Program Durable Cell Therapies

    by Franziska Blaeschke, Yan Yi Chen, Ryan Apathy, Zhongmei Li, Cody T. Mowery, William A. Nyberg, Angela To, Ruby Yu, Raymund Bueno, Min Cheol Kim, et al.

    SUMMARY: Chronic stimulation can cause T cell dysfunction and limit efficacy of cellular immunotherapies. CRISPR screens have nominated gene targets for engineered T cells, but improved methods are required to compare large numbers of synthetic knockin sequences to reprogram cell functions. Here, we developed Modular Pooled Knockin Screening (ModPoKI), an adaptable platform for modular construction of DNA knockin libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors. Over 20 ModPoKI screens across human TCR and CAR T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct to enhance long-term T cell fitness and anti-cancer function in vitro and in vivo . ModPoKI’s modularity allowed us to generate a ∼10,000-member library of TF combinations. Non-viral knockin of a combined BATF-TFAP4 polycistronic construct further enhanced function in vivo . ModPoKI facilitates discovery of complex gene constructs to program cellular functions. Highlights: Modular pooled knockins of hundreds of TF and surface receptor constructs combined with different antigen receptors Chronic stimulation screens discover programs to improve T cell persistence Combinatorial knockin screens with ∼10,000 transcription factor combinations BATF-TFAP4 dual knockin construct improves CAR T cell function in vitro and in vivo